Cyteir Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 11.82 million compared to USD 5.36 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 2.92 a year ago.
Cyteir Therapeutics, Inc.
Equities
CYTT
US23284P1030
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |